VCELVericel Corporation

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M-23.5% YoY

Gross Profit

$11M56.7% margin

Operating Income

-$8M-41.8% margin

Net Income

-$8M-41.3% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-25.0%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$147M

Total Liabilities

$39M

Stockholders' Equity

$108M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$26M	-23.5%
Gross Profit	$11M	$17M	-33.7%
Operating Income	-$8M	-$20M	+58.6%
Net Income	-$8M	-$20M	+58.2%

VCEL Q2 2020 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena